Current State of Use of Evidence- Based Therapies for Acute Coronary Syndromes Strategies to Improve Implementation of Guidelines-Based Care Strategies.

Slides:



Advertisements
Similar presentations
ACTION Registry (Acute Coronary Treatment and Intervention Outcomes Network) Initial Report 1st Quarter 2007 Results Report prepared by: www. ncdr.com.
Advertisements

© 2010, American Heart Association. All rights reserved. Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained.
Acute Myocardial Infarction (AMI) JCAHO Core Measure Project Loyola University Medical Center Team Members: K. McLean MD, M. Morrow MSN, J. Cochran BSN,
What Have We Learned from the CRUSADE Registry
GAP-D2B An Alliance for Quality. GAP-D2B Goal n To achieve a door-to-balloon time of
Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly Findings From the Get With the Guidelines Quality-
Regional Differences in Quality of Care and Outcomes for the Treatment of Acute Coronary Syndromes: An Analysis from the Get With The Guidelines Program.
Rationale and Design of the Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) at the University of California Los Angeles Gregg C. Fonarow,
The Relationship Between CMS Quality Indicators and Long-term Outcomes Among Hospitalized Heart Failure Patients Mark Patterson, Ph.D., M.P.H. Post-doctoral.
Are Quality Improvements Associated with the GWTG-Coronary Artery Disease (GWTG-CAD) Program Sustained Over Time? A Longitudinal Comparison of GWTG-CAD.
Closing the CHD Treatment GAP Saving Lives Through Better Implementation of Secondary Prevention Measures.
Use of REMIND Artificial Intelligence Software for Rapid Assessment of Adherence to Disease Specific Management Guidelines in Acute Coronary Syndromes.
Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelines– Coronary.
What is the Most Efficient Data Extraction Method for Quality Improvement and Research in Cardiology?: A Comparison of REMIND Artificial Intelligence Software.
© American Heart Association 2001 Nathan D. Wong, PhD, FACC.
Development of Clinical Pathways to Streamline Care for Patients Presenting with Suspected Cardiac Chest Pain Background The National Heart Foundation.
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
The Relationship Between Organizational Factors and Performance Among Pay-for- Performance Hospitals Vina ER, Rhew DC, Weingarten SR, Weingarten JB, Chang.
Unstable Angina /Non-ST Elevation Myocardial Infarction Critical Pathway Toolkit Adapted from Dr Chris Cannon STRIVE Scientific Committee – 2008 Based.
Congestive Heart Failure Quality Initiatives. SRHS History of CHF Focus Team early 90’s, developed Care Map, adopted education materials and guidelines.
QI ACTION Registry-Get With The Guidelines The Mission Lifeline Data Solution Kathleen O’Neill, MHA Senior Director, Quality Initiatives IL & SD American.
CRUSADE: A National Quality Improvement Initiative CRUSADE: A National Quality Improvement Initiative Can Rapid Risk Stratification of Unstable Angina.
Sue Huckson Program Manager National Institute of Clinical Studies Improving care for Mental Health patients in Emergency Departments.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
STRIVE TM What Is the Evidence That Critical Pathways Work? UCLA Cardiac Hospitalization Atherosclerosis Management Program (CHAMP) ACC Guidelines Applied.
Quality of care, part 2: heart failure Kim A Eagle MD Albion Walter Hewlett Professor of Internal Medicine Chief, Clinical Cardiology Co-Director, Heart.
Pay for Performance: Choosing Measures Linda K. Shelton AVP, Product Development PFP Boot Camp for Physicians and Physician Organizations February 2006.
ACUTE MYOCARDIAL INFARCTION Team Membership Clinical Departments: Cardiology, Cardiovascular Surgery, Emergency Medical Services Hospital Departments:
1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 
1 Acute Myocardial Infarction and the Role of Critical Pathways Christopher Cannon, M.D. Brigham and Women’s Hospital Boston.
” “The Dissociation Between Door-to- Balloon Time Improvement and Improvements in Other Acute Myocardial Infarction Care Processes and Patient Outcomes”
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
ACS Clinical Pathway. Who? Pts with Acute Ischemic Heart Disease now described as having ACS.
The IC 3 (Improving Continuous Cardiac Care) - PINNACLE Program: A Report of the first 14,000+ Patients Paul S. Chan, MD MScWilliam J. Oetgen, MD Donna.
Pharmacy 483: Steve Riddle, BS Pharm, BCPS QI and Medication Utilization Lead HMC Pharmacy February 22, 2005 Quality Improvement in Pharmacy.
Integrating AMI Care Across a Healthcare Service System Safer Healthcare Now National WebEx October 19 th, 2009 Diane Shanks and Leila Lavorato.
Acute Myocardial Infarction (Heart Attack) Committee Membership: B. Majcher, APRN, C. Mulhall, APRN, K. McLean, MD, M. Jarotkiewicz RRT, MS, Administrative.
What are we trying to do?. Acute Phase Driver Diagram.
National AMI Information Call February 5, 2008 Patient Safety Initiative.
Quality of care, part 4: MI Kim A Eagle MD Albion Walter Hewlett Professor of Internal Medicine Chief, Clinical Cardiology Co-Director, Heart Care Program.
0009COR1 A CRUSADE to Improve Quality of Care for ACS Patients Eric D. Peterson, MD, MPH Associate Professor of Medicine Director of CV Outcomes and Quality.
“Challenging practice in non-ST segment elevation Acute Coronary Syndromes (ACS)” Professor Jennifer Adgey Royal Victoria Hospital, Belfast 26th January.
6/04 CRUSADE: A National Quality Improvement Initiative C an R apid Risk Stratification of U nstable Angina Patients S uppress AD verse Outcomes with E.
Using drug use evaluation (DUE) to optimise analgesic prescribing in emergency departments (EDs) Karen Kaye, Susie Welch. NSW Therapeutic Advisory Group*
Pharmacotherapy in acute coronary syndromes Perspective from first line and regional hospitals in Czech Republic Cardionale, Petr Jansky.
Clinical Trial Results. org Characteristics, Management, and Outcomes of 5,557 Patients Age ≥90 Years With Acute Coronary Syndromes: Results From the CRUSADE.
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
Perspectives on Inter-Hospital AMI Care: Timing & Documentation at the New Brunswick Heart Centre Cleo Cyr RN, BN, MHS Saint John, NB.
Managing AMI – much work still to do? MONDAY, 28 th FEBRUARY – SESSION 3 Patrick Goldstein EXPERTS WORKSHOP ON EARLY TREATMENT STRATEGIES FOR ACUTE MYOCARDIAL.
Acute Myocardial Infarction February 8, 2006.
Key Indicator Components % ASA within 24 hrs of admission % ASA within 24 hrs of admission Reperfusion time (STEMI) Reperfusion time (STEMI) Door to needle.
Management of Patients with NSTE ACS Latest Insights from CRUSADE A National Quality Improvement Initiative Eric D. Peterson, MD, MPH Duke Clinical Research.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Management Strategies for Post-Intervention in Patients with CAD VBWG.
Overview of the Winnipeg CODE STEMI Project Implemented May 2008 Dr.J.Tam MD, FRCP(C), FACC Section Chief Cardiology WRHA and University of Manitoba Lillian.
HEART FAILURE TEAM MEMBERSHIP DEPARTMENTS OF CARDIOLOGY, CARDIOVASCULAR SURGERY, MEDICINE, NURSING, QUALITY AND RESOURCE MANAGEMENT, THE CENTER FOR CLINICAL.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Presidential address: quality of cardiovascular.
Eva Kline-Rogers RN, NP, AACC University of Michigan
Brief History on Mission: Lifeline
Nicholas D Hartman, M. D. , M. P. H. 1, Kim L. Askew, M. D. 1, David E
The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,
Section F: Clinical guidelines
2006 CRUSADE 2nd Quarter Results
An Analysis of the ACUITY Trial Lincoff AM, JACC Intv 2008;1:639–48
What Have We Learned from the CRUSADE Registry
Quality Improvement Programs and Critical Pathways
Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Current State of Use of Evidence- Based Therapies for Acute Coronary Syndromes Strategies to Improve Implementation of Guidelines-Based Care Strategies to Improve Implementation of Guidelines-Based Care

AHA/ACC Guideline Recommendations n Aspirin l Clopidogrel n Beta-Blocker n ACE-Inhibitor n Heparin (UFH or LMWH) n GP IIbIIIa Inhibitor l High-risk patients l All receiving PCI n Aspirin l Clopidogrel n Beta-Blocker n ACE-Inhibitor n Heparin (UFH or LMWH) n GP IIbIIIa Inhibitor l High-risk patients l All receiving PCI n Aspirin l Clopidogrel n Beta-Blocker n ACE-Inhibitor n Statin n Smoking Cessation n Cardiac Rehab Acute Therapy Discharge Therapy JACC 2000;36: ACC/AHA 2002 Update JACC 2000;36: ACC/AHA 2002 Update

NRMI-4 NSTE MI Acute Care : 3rd Quarter 2001

NRMI-4 NSTE MI Discharge Care : 3rd Quarter % 75% 56% 71% 21% 0% 20% 40% 60% 80% 100% ASABeta BlockerACE Inhibitor * Statins #Cardiac Rehab * LVEF < 40% # Known hyperlipidemia * LVEF < 40% # Known hyperlipidemia

Performance Quality IndicatorBottom 10% Top 10% ASA use < 24 h54%99%  -blocker use < 24 h33%98% Heparin use <24 h50%92% GP IIb-IIIa < 24 h0%51% D/C ASA use 54%99% D/C  -blocker use44%96% D/C ACE-I use21%83% D/C lipid lowering33%99% Performance Quality IndicatorBottom 10% Top 10% ASA use < 24 h54%99%  -blocker use < 24 h33%98% Heparin use <24 h50%92% GP IIb-IIIa < 24 h0%51% D/C ASA use 54%99% D/C  -blocker use44%96% D/C ACE-I use21%83% D/C lipid lowering33%99% Gap between ‘Leading and Lagging’ US Hospitals

Evidence-Based Medicine: What’s the Problem? “There is an unsettling truth about the practice of medicine. …study after study shows that few physicians systematically apply to everyday treatment the scientific evidence about what works best.” Millenson, ML. Demanding Medical Excellence: Doctors and Accountability in the Information Age, 1997 Millenson, ML. Demanding Medical Excellence: Doctors and Accountability in the Information Age, 1997

Physician Barriers to Guidelines Adherence n Lack of awareness or agreement with guidelines n Lack of outcome expectancy l Uncertainty regarding impact of guidelines adherence on patient outcomes n Overcoming established practice patterns n External barriers to improved care l Time constraints, lack of resources, no reminders n Lack of awareness or agreement with guidelines n Lack of outcome expectancy l Uncertainty regarding impact of guidelines adherence on patient outcomes n Overcoming established practice patterns n External barriers to improved care l Time constraints, lack of resources, no reminders Cabana M, JAMA 1999

Does it Matter? Correlating Process of Care with Outcomes

Additional Lives Additional Lives Current Use Saved per 1,000 Therapy(ideal pts)(ideal use) Aspirin86%9 Beta-Blockers59%11 ACE-Inhibitors52%23 Ca 2+ Blockers * 27%*13 Total56 Additional Lives Additional Lives Current Use Saved per 1,000 Therapy(ideal pts)(ideal use) Aspirin86%9 Beta-Blockers59%11 ACE-Inhibitors52%23 Ca 2+ Blockers * 27%*13 Total56 Alexander K, JACC, 1998 * Contraindicated use in low EF pts Ideal benefits from 0% use Ideal benefits from 0% use * Contraindicated use in low EF pts Ideal benefits from 0% use Ideal benefits from 0% use Benefits of Using Evidence-Based Therapies (Non-ST  ACS Patients from GUSTO IIb)

US News and World Reports’ “Top Ranked Hospitals” Chen J, NEJM, 1999 p < 0.01

Adherence to ACC/AHA Guidelines and Mortality: Results from NRMI-4 (n= 57,806 Acute MI patients, 1185 hospitals) %50-60%60-70%>70% % In-hospital Mortality Rate of Hospital Composite Adherence (13 Indicators) Rate of Hospital Composite Adherence (13 Indicators) Peterson E, ACC 2002

Local Quality Improvement Initiative Francis M. Fesmire, MD Erlanger Medical Center Chattanooga, TN Francis M. Fesmire, MD Erlanger Medical Center Chattanooga, TN

Erlanger QI Project - Objectives n Determine early utilization of GP IIb-IIIa inhibitors use in ED in high-risk NSTE ACS patients n Implement stepped QI program n Re-measure effectiveness of QI program n Determine early utilization of GP IIb-IIIa inhibitors use in ED in high-risk NSTE ACS patients n Implement stepped QI program n Re-measure effectiveness of QI program

n Prospective Observational Study n 2,074 patients presenting with chest pain n Patients not undergoing urgent cardiac cath underwent standard Chest Pain Evaluation Protocol at Erlanger n Prospective Observational Study n 2,074 patients presenting with chest pain n Patients not undergoing urgent cardiac cath underwent standard Chest Pain Evaluation Protocol at Erlanger Erlanger QI Project - Methods

n Control (months 1-4): No intervention n Phase I (months 5-8): Posted eligibility criteria for GP IIb/IIIa inhibitors in ED n Phase II (months 9-12): Mandated QI form for completion by the evaluating ED physician with weekly review and feedback n Control (months 1-4): No intervention n Phase I (months 5-8): Posted eligibility criteria for GP IIb/IIIa inhibitors in ED n Phase II (months 9-12): Mandated QI form for completion by the evaluating ED physician with weekly review and feedback Erlanger QI Project - Interventions

n % of patients who received GP IIb/IIIa inhibitors: l Control Phase: 6% l Phase I QI Intervention: 16% l Phase II QI Intervention: 45% n % of patients who received GP IIb/IIIa inhibitors: l Control Phase: 6% l Phase I QI Intervention: 16% l Phase II QI Intervention: 45% Erlanger QI Project - Results (1)

n Reasons for not treatment in Phase II l 63% - ED Physician Never Realized Eligibility l 24% - Treatment was perceived to delay transfer to the cardiac cath lab l 10% - Admitting Physician did not want GP IIb/IIIa inhibitors to be administered l 3% - Contraindication n Reasons for not treatment in Phase II l 63% - ED Physician Never Realized Eligibility l 24% - Treatment was perceived to delay transfer to the cardiac cath lab l 10% - Admitting Physician did not want GP IIb/IIIa inhibitors to be administered l 3% - Contraindication Erlanger QI Project - Results (2)

UCLA Cardiovascular Hospitalization Atherosclerosis Management Program (CHAMP) Gregg C. Fonarow, MD; Anna Gawlinski, DNSc Am J Cardiol 2000;85:10A-17A Am J Cardiol 2001;87:

CHAMP - Program Overview (1) n CHAMP focused on the in-hospital initiation of: l Aspirin l Cholesterol-lowering therapy (statins) l Beta-blockers l ACE-Inhibitors n Medical interventions were done together with diet, exercise, and smoking cessation counseling before discharge in patients with acute MI n CHAMP focused on the in-hospital initiation of: l Aspirin l Cholesterol-lowering therapy (statins) l Beta-blockers l ACE-Inhibitors n Medical interventions were done together with diet, exercise, and smoking cessation counseling before discharge in patients with acute MI Am J Cardiol 2000;85:10A-17A

CHAMP - Program Overview (2) n Implementation of CHAMP involved the use of: l Focused treatment guidelines l Standardized admission orders l Educational lectures by local thought leaders l Tracking and reporting of medication treatment rates n Treatment rates and clinical outcomes were compared in patients with acute MI discharged in the 2-year periods before and after CHAMP was implemented n Implementation of CHAMP involved the use of: l Focused treatment guidelines l Standardized admission orders l Educational lectures by local thought leaders l Tracking and reporting of medication treatment rates n Treatment rates and clinical outcomes were compared in patients with acute MI discharged in the 2-year periods before and after CHAMP was implemented Am J Cardiol 2000;85:10A-17A

Medication Utilization Rates at Discharge Pre-CHAMPPost-CHAMP ( )( ) Discharge Therapy (n=256) (n=302)p-value Aspirin 78 92<0.001 Beta-Blockers 12 61<0.001 Nitrates 62 34<0.01 Calcium Antagonists 68 12<0.001 ACE-Inhibitors 4 56<0.001 Statins 6 86< Am J Cardiol 2000;85:10A-17A

77 NRMI Data from UCLA compared to 1437 other NRMI Hospitals UCLA CHAMP - Sustained Impact Over 6 Years

Regional Quality Improvement Initiative: The Guidelines Applied in Practice (“GAP”) Initiative in Southeast Michigan Kim A. Eagle, M.D. University of Michigan

Partnership   GAP Committee   AMI Committee GDAHC   Michigan Peer Review Organization   QI Network   Measurement   Greater Detroit Area Health Council   Employers, Insurers Providers MPRO ACC

GAP Toolkit for AMI Care n Standard Orders n Pocket Guidelines Cards n Clinical Pathways n Patient Information Forms n Patient Discharge Forms (Flight plan) n Hospital Performance Charts n Chart Stickers n Standard Orders n Pocket Guidelines Cards n Clinical Pathways n Patient Information Forms n Patient Discharge Forms (Flight plan) n Hospital Performance Charts n Chart Stickers

Hospital Selection Project Kick-off Presentation Individual Hospital Kick-off Project Implementation Hospital Remeasurement Data Analysis Major Results Presentation March 2001 January – February 2001 September – December 2000 March – September 2000 March 2000 February 2000 April- June 2000 GAP Rapid Cycle Change

64% 65% 81% 70% 87% 74% 0% 20% 40% 60% 80% 100% (343) (404) (213) (245) (131) (252) (343) (404) (213) (245) (131) (252) ASA BB LDL CHOL * * Time in Minutes (40) (24) (32) (45) LYSIS PTCA PTCA PRE POST GAP Results: Early Indicators (Aggregate) * p < 0.05 ** p < 0.01

68% 53% 80% 84% 89% 75% 65% 86% 92% 93% 0% 20% 40% 60% 80% 100% GAP Results: Late Indicators (Aggregate) (267) (406) (106) (146) (139) (173) (159) (226) (112) (209) ASA BB ACE SMOKING CHOL RX ASA BB ACE SMOKING CHOL RX * ** PRE POST * p < 0.05 ** p < 0.01

GAP Conclusions n Performance regarding early quality indicators is enhanced when AMI-specific standard order sets are used n Adherence to late quality indicators is enhanced by use of an AMI-specific standard discharge tool n Further studies are underway to compare the performance levels achieved in GAP hospitals to non-GAP hospitals in the region n Performance regarding early quality indicators is enhanced when AMI-specific standard order sets are used n Adherence to late quality indicators is enhanced by use of an AMI-specific standard discharge tool n Further studies are underway to compare the performance levels achieved in GAP hospitals to non-GAP hospitals in the region

Challenges to Improved Patient Care Poor knowledge of best treatments Lack of use of best treatments Lack of systems to collect and understand clinical information Lack of knowledge of how to influence practice

Concept Outcomes Clinical Trials Guidelines Performance Indicators Performance Indicators PerformancePerformance The Cycle of Clinical Therapeutics

Mobilization Identify Physician Champions Establish Local Consensus Planning Local Education Develop Hospital Plan Build Local QI Team Implementation Collect Baseline Data Care Pathways Feedback  Intervention Review local treatment data Determine need for improvement Develop targeted interventions Process of Continuous Quality Improvement (CQI)

Strategies to Improve Patient Care n Physician Continuing Medical Education n Local Opinion Leaders/Champions n Regular Feedback on Performance n Reminders, Care Pathways, Algorithms n Patient-Oriented Interventions n Total Quality Management - Multifaceted Interventions n Physician Continuing Medical Education n Local Opinion Leaders/Champions n Regular Feedback on Performance n Reminders, Care Pathways, Algorithms n Patient-Oriented Interventions n Total Quality Management - Multifaceted Interventions Grol R, JAMA 2001

Quality Improvement Interventions: Predictors of Success n Shared goals among health care providers regarding use of evidence-based therapies n Administrative support for CQI projects n Strong leadership by physician “champions” for improved patient care n High-quality data feedback mechanisms n Shared goals among health care providers regarding use of evidence-based therapies n Administrative support for CQI projects n Strong leadership by physician “champions” for improved patient care n High-quality data feedback mechanisms Bradley E, JAMA Use of Beta-Blockers Post-MI

Practical Steps to Improve the Use of Evidence-Based Therapies for Non-ST  ACS n Improve physicians’ knowledge of the ACC/AHA practice guidelines n Encourage cooperation between Emergency Medicine physicians and Cardiologists n Accurately track adherence to treatment recommendations from the guidelines n Secure institutional commitment to improved patient care with guidelines implementation n Improve physicians’ knowledge of the ACC/AHA practice guidelines n Encourage cooperation between Emergency Medicine physicians and Cardiologists n Accurately track adherence to treatment recommendations from the guidelines n Secure institutional commitment to improved patient care with guidelines implementation

Steps for Improved ACS Care n Utilize simple data collection tools n Encourage multi-disciplinary collaboration n Study entire spectrum of ACS n Continuously update clinical practice guidelines n Mandate quality monitoring for all hospitals n Tie financial reimbursement to quality of care n Utilize simple data collection tools n Encourage multi-disciplinary collaboration n Study entire spectrum of ACS n Continuously update clinical practice guidelines n Mandate quality monitoring for all hospitals n Tie financial reimbursement to quality of care